4SC AG receives Paediatric Investigation Plan waiver ...
4SC AG received a PIP waiver from UK MHRA for resminostat, an oral treatment for advanced CTCL, eliminating the need for paediatric studies. This aids in advancing the Marketing Authorisation Application in the UK. 4SC has also filed applications with EMA, FDA, and is preparing for UK and Switzerland submissions.
Reference News
4SC AG receives Paediatric Investigation Plan waiver ...
4SC AG received a PIP waiver from UK MHRA for resminostat, an oral treatment for advanced CTCL, eliminating the need for paediatric studies. This aids in advancing the Marketing Authorisation Application in the UK. 4SC has also filed applications with EMA, FDA, and is preparing for UK and Switzerland submissions.